229 related articles for article (PubMed ID: 25293770)
1. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.
Liu TM; Ling Y; Woyach JA; Beckwith K; Yeh YY; Hertlein E; Zhang X; Lehman A; Awan F; Jones JA; Andritsos LA; Maddocks K; MacMurray J; Salunke SB; Chen CS; Phelps MA; Byrd JC; Johnson AJ
Blood; 2015 Jan; 125(2):284-95. PubMed ID: 25293770
[TBL] [Abstract][Full Text] [Related]
2. Novel target to kill CLL.
Robak T; Smolewski P
Blood; 2015 Jan; 125(2):211-2. PubMed ID: 25573966
[TBL] [Abstract][Full Text] [Related]
3. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
Mani R; Mao Y; Frissora FW; Chiang CL; Wang J; Zhao Y; Wu Y; Yu B; Yan R; Mo X; Yu L; Flynn J; Jones J; Andritsos L; Baskar S; Rader C; Phelps MA; Chen CS; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
Leukemia; 2015 Feb; 29(2):346-55. PubMed ID: 24947019
[TBL] [Abstract][Full Text] [Related]
4. AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1.
Schrader A; Popal W; Lilienthal N; Crispatzu G; Mayer P; Jones D; Hallek M; Herling M
Curr Cancer Drug Targets; 2014; 14(8):700-12. PubMed ID: 25348018
[TBL] [Abstract][Full Text] [Related]
5. Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
Redondo-Muñoz J; Escobar-Díaz E; Hernández Del Cerro M; Pandiella A; Terol MJ; García-Marco JA; García-Pardo A
Clin Cancer Res; 2010 Sep; 16(17):4382-91. PubMed ID: 20534739
[TBL] [Abstract][Full Text] [Related]
6. T315 Decreases Acute Myeloid Leukemia Cell Viability through a Combination of Apoptosis Induction and Autophagic Cell Death.
Chiu CF; Weng JR; Jadhav A; Wu CY; Sargeant AM; Bai LY
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27537872
[TBL] [Abstract][Full Text] [Related]
7. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
[TBL] [Abstract][Full Text] [Related]
8. The Novel Small Molecule Inhibitor, OSU-T315, Suppresses Vestibular Schwannoma and Meningioma Growth by Inhibiting PDK2 Function in the AKT Pathway Activation.
Mercado-Pimentel ME; Igarashi S; Dunn AM; Behbahani M; Miller C; Read CM; Jacob A
Austin J Med Oncol; 2016; 3(1):. PubMed ID: 27642646
[TBL] [Abstract][Full Text] [Related]
9. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C
Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224
[TBL] [Abstract][Full Text] [Related]
10. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG
Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528
[TBL] [Abstract][Full Text] [Related]
11. OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway.
Bai LY; Ma Y; Kulp SK; Wang SH; Chiu CF; Frissora F; Mani R; Mo X; Jarjoura D; Byrd JC; Chen CS; Muthusamy N
Br J Haematol; 2011 Jun; 153(5):623-33. PubMed ID: 21470196
[TBL] [Abstract][Full Text] [Related]
12. AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
Cosimo E; Tarafdar A; Moles MW; Holroyd AK; Malik N; Catherwood MA; Hay J; Dunn KM; Macdonald AM; Guichard SM; O'Rourke D; Leach MT; Sansom OJ; Cosulich SC; McCaig AM; Michie AM
Clin Cancer Res; 2019 Mar; 25(5):1574-1587. PubMed ID: 30559170
[TBL] [Abstract][Full Text] [Related]
13. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
14. OSU-03012 Disrupts Akt Signaling and Prevents Endometrial Carcinoma Progression in vitro and in vivo.
Ding L; Ren C; Yang L; Wu Z; Li F; Jiang D; Zhu Y; Lu J
Drug Des Devel Ther; 2021; 15():1797-1810. PubMed ID: 33958857
[TBL] [Abstract][Full Text] [Related]
15. Activation of Protein Tyrosine Phosphatase Receptor Type γ Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells.
Montresor A; Toffali L; Fumagalli L; Constantin G; Rigo A; Ferrarini I; Vinante F; Laudanna C
J Immunol; 2021 Jul; 207(2):671-684. PubMed ID: 34162728
[TBL] [Abstract][Full Text] [Related]
16. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
17. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.
Herling M; Patel KA; Weit N; Lilienthal N; Hallek M; Keating MJ; Jones D
Blood; 2009 Nov; 114(21):4675-86. PubMed ID: 19770358
[TBL] [Abstract][Full Text] [Related]
18. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia.
Goussetis DJ; Platanias LC
Clin Cancer Res; 2010 Sep; 16(17):4311-2. PubMed ID: 20622048
[TBL] [Abstract][Full Text] [Related]
20. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
